Home
Market Watch
Portfolio Manager
Top
Advertisement
Highlights:

Last Price Change Volume
KLSE Market Watch
Open: Day Range: Prev Close:
Charting
TechnicalChart
Market Date: 20 Nov 2017

Trade Detail

Trade Value (RM)
VWAP (RM)
4 Weeks Range
4 Weeks Change (%)
Avg Volume (4 Weeks)
1 Year Range
1 Year Change (%)
Avg Volume (1 Year)

Market Capital (RM)
Number of Share
EPS (cent)
P/E Ratio
ROE (%)
Dividend (cent)
Dividend Yield (%)
Dividend Policy (%)
NTA (RM)
Par Value (RM)

* Calculated based on the net profit of the trailing twelve months and latest number of shares issued.

DateFinancial
Year
No. Financial
Quarter
Revenue
(RM,000)
PBT (RM,000)Net Profit
(RM,000)
EPS (Cent)Dividend
(Cent)
NTA
(RM)
Download
Report
13 Nov 201730 Jun 2018130 Sep 201749,6572,9722,1300.260.000.244 Malaysia Stock - KLSE Quarter Report History
30 Aug 201730 Jun 2017430 Jun 201735,584-6,822-6,358-0.770.000.241 Malaysia Stock - KLSE Quarter Report History
24 May 201730 Jun 2017331 Mar 201740,875-5,440-4,140-0.500.000.249 Malaysia Stock - KLSE Quarter Report History
23 Feb 201730 Jun 2017231 Dec 201649,3376,0714,9210.600.000.254 Malaysia Stock - KLSE Quarter Report History
22 Nov 201630 Jun 2017130 Sep 201644,1395,1414,0990.500.500.253 Malaysia Stock - KLSE Quarter Report History
30 Aug 201630 Jun 2016430 Jun 201651,1407,0426,2160.760.000.248 Malaysia Stock - KLSE Quarter Report History
24 May 201630 Jun 2016331 Mar 201640,8931,9911,4800.180.000.237 Malaysia Stock - KLSE Quarter Report History
18 Feb 201630 Jun 2016231 Dec 201555,9446,0244,0460.510.000.236 Malaysia Stock - KLSE Quarter Report History
26 Nov 201530 Jun 2016130 Sep 201541,0497,6376,1540.790.850.241 Malaysia Stock - KLSE Quarter Report History
28 Aug 201530 Jun 2015430 Jun 201542,6986,2984,7990.620.000.235 Malaysia Stock - KLSE Quarter Report History
29 May 201530 Jun 2015331 Mar 201548,6537,4746,0300.790.500.220 Malaysia Stock - KLSE Quarter Report History
25 Feb 201530 Jun 2015231 Dec 201448,1456,0474,5670.600.000.217 Malaysia Stock - KLSE Quarter Report History
1234

DateFinancial
Year
Ex-DateEntitlement
Date
Payment
Date
Entitlement TypeDividend
(Cent)
Dividend
(%)
Details
30 Aug 201630 Jun 201613 Sep 201615 Sep 201611 Oct 2016Interim Dividend0.50000.00 Malaysia Stock -  Dividend
28 Aug 201530 Jun 201511 Sep 201515 Sep 201502 Oct 2015Interim Dividend0.50000.00 Malaysia Stock -  Dividend
28 Aug 201530 Jun 201511 Sep 201515 Sep 201502 Oct 2015Special Dividend0.35000.00 Malaysia Stock -  Dividend
25 Feb 201530 Jun 201510 Mar 201512 Mar 201527 Mar 2015Interim Dividend0.50000.00 Malaysia Stock -  Dividend
21 Mar 201430 Jun 201402 Apr 201404 Apr 201418 Apr 2014Interim Dividend0.50000.00 Malaysia Stock -  Dividend
15 May 200830 Jun 200829 May 200802 Jun 200801 Jul 2008Interim Dividend1.10000.00 Malaysia Stock -  Dividend
14 Dec 200630 Jun 200703 Jan 200705 Jan 200722 Jan 2007Interim Dividend3.50000.00 Malaysia Stock -  Dividend

DateEx-DateEntitlement
Date
Transfer
Date
TypeRatioRight Issue
Price
Details
25 Apr 201308 May 201310 May 201310 May 2013Rights Issue1 : 20.020 Malaysia Stock -  Bonus/Rights Issue
01 Dec 201113 Dec 201115 Dec 201115 Dec 2011Dividend In Specie25 : 1000.000 Malaysia Stock -  Bonus/Rights Issue
11 Dec 200724 Dec 200727 Dec 200727 Dec 2007Rights Issue1 : 20.020 Malaysia Stock -  Bonus/Rights Issue
22 Dec 200611 Jan 200715 Jan 200715 Jan 2007Others5 : 10.000 Malaysia Stock -  Bonus/Rights Issue
06 Dec 200522 Dec 200527 Dec 200527 Dec 2005Bonus Issue3 : 50.000 Malaysia Stock -  Bonus/Rights Issue

HOVID (7213) : HOVID BERHAD
Mike
Member Star
Posts: 84
Joined: Dec 2011
Male, MYS
16 Jan 2012, 08:11 PMPost #1
Is HOVID( PN17) really coming up this time ?question
Mike
Member Star
Posts: 84
Joined: Dec 2011
Male, MYS
17 Jan 2012, 08:39 AMPost #2
Today Hovid uplifted the PN17,is price can going up ?
KLSETrader
Member Star
Posts: 38
Joined: Jan 2012
Female, MYS
17 Jan 2012, 08:47 AMPost #3
Look good for the Q price, but be careful in case any profit taking today..smile
tingtaimeng
Member Star
Posts: 37
Joined: Dec 2013
Male, MYS
31 Dec 2013, 05:13 PMPost #4
又要上了。thumbuprolleyes
CNY2012
Member Star
Posts: 106
Joined: Dec 2011
Female, MYS
25 Feb 2014, 03:37 PMPost #5
CIMB Research keeps Hovid target price at 43 sen

KUALA LUMPUR: CIMB Equities Research is maintaining its Add call for Hovid and target price of 43 sen, which is 23.1% above the last traded price of 35 sen.

It said on Tuesday that despite meeting just 39% of its full-year forecast and 33% of consensus numbers, Hovid’s 1HFY6/14 core net profit was broadly in line with expectations as 2H should be stronger due to seasonally higher sales and the weaker ringgit which will boost exports.

“We maintain our Add call, earnings forecasts and SOP-based target price. Increased product registrations in export markets and stronger 2H earnings could spark a re-rating,” it said.

CIMB Research said Hovid's 2Q net profit fell 13% on-year to RM3.7mil because a higher portion of its sales came from lower-margin products. This led to a fall in EBITDA margin from 17.6% a year earlier to 14.4%.

“We suspect that EBITDA margin may also have been crimped by higher operational costs, probably due to the introduction of the minimum wage policy early last year.

“We expect Hovid to report stronger earnings in 2H due to seasonally stronger sales. On top of that, Hovid is a beneficiary of the weak ringgit because half of its revenue is derived from export sales, which are predominantly quoted in US$.

“The ringgit has averaged 3.31 to the greenback year-to-date, 3% weaker than the average in July-December 2013. The company is also actively pushing its export sales by registering its existing products with the health authorities in the export markets.

“It plans to roll out 10-15 products this year, which should expand its existing 400-strong product range by 3-4%. Increased registrations of Hovid's drugs in its export markets will spur demand as more products are made available in these export markets. This will help to widen its profit margin and lead to higher profitability,” it said.

CIMB Research said it likes Hovid's strong long-term earnings growth prospects as the pharmaceutical markets in Malaysia and its key export destinations are set to grow at double-digit rates, driven by ageing populations and greater access to healthcare services and medicines.

Hovid remains its top pick for exposure to the Malaysian healthcare sector. Potential re-rating catalysts are increased product registrations in its export markets and stronger 2H earnings.
TonyCHO
Member Star
Posts: 2
Joined: Apr 2015
Male, MYS
13 Apr 2015, 04:57 PMPost #6
questionHOVID大概会升到多少??

yeah doh drool lol mad notworthy question rant rolleyes sad shutup shy smile star sweat thumbup wub cry

Close